A sensitive [Na,K]ATPase assay specific for inhibitors acting through the digitalis-binding site

Area of Science:

• Biochemistry
• Pharmacology
• Physiology

Background:

• Studying endogenous sodium pump inhibitors (ESPIs) is challenging due to the lack of specificity in current assays.
• A novel, more sensitive assay for [Na,K]ATPase inhibition has been developed, incorporating a prereaction step to increase binding affinity of digitalis-like molecules.

Purpose of the Study:

• To determine if the enhanced inhibition observed in the sensitive assay is specific to inhibitors acting via the digitalis-binding site.
• To differentiate between specific and nonspecific ESPI candidates using both standard and sensitive [Na,K]ATPase assays.

Main Methods:

• Comparison of inhibition levels using standard and sensitive [Na,K]ATPase assays.
• Testing known specific inhibitors (ouabain, digoxin, bufalin) and proposed ESPI candidates (oleic acid, lysophosphatidyl choline, vanadate, and a peritoneal dialysate ESPI).

Main Results:

• Specific inhibitors (ouabain, digoxin, bufalin) showed significantly increased inhibition in the sensitive assay compared to the standard assay.
• Nonspecific inhibitors (oleic acid, lysophosphatidyl choline, vanadate) showed no significant difference in inhibition between the two assays.
• An ESPI from peritoneal dialysate, with unknown specificity, demonstrated enhanced inhibition in the sensitive assay.

Conclusions:

• The sensitive [Na,K]ATPase assay, when used with a standard assay, can effectively identify ESPI candidates that interact specifically with the digitalis receptor.
• This approach facilitates the early determination of specific endogenous sodium pump inhibitors.